Cardiac Amyloidosis
Learn about Cardiac Amyloidosis (Amyloid Cardiomyopathy), including ATTR-CM and AL Amyloidosis with cardiac involvement. This resource provides information on diagnosis, clinical documentation, and medical coding for healthcare professionals. Find details on ICD-10 codes, symptoms, treatment, and management of Cardiac Amyloidosis for accurate and efficient clinical documentation and coding.
A disorder where abnormal protein (amyloid) builds up in the heart muscle, affecting its function.
Shortness of breath, fatigue, swelling, irregular heartbeat, dizziness, and syncope.
Outpatient cardiology clinics, heart failure clinics, and specialized amyloidosis centers.
ICD-10 Code Families
Complete code families applicable to E85.4
When to use each related code
| Description | When to use |
|---|---|
| Heart muscle weakened by amyloid protein deposits. | Cardiac symptoms (e.g., shortness of breath, fatigue) with suspected amyloid deposits. Consider ATTR-CM, AL amyloidosis subtypes. |
| Systemic light-chain amyloidosis affecting the heart. | Heart involvement in AL amyloidosis. Look for plasma cell dyscrasia, multi-organ involvement. |
| Heart failure due to abnormal transthyretin protein buildup. | Heart failure with neuropathy (e.g., carpal tunnel). Genetic testing can confirm hereditary ATTR-CM. |
Best-practice checklist
- ✓Cardiac amyloidosis diagnosis: document amyloid type (AL, ATTR, etc.)
- ✓Amyloid cardiomyopathy: specify organ involvement (e.g., heart, kidneys)
- ✓ATTR-CM: include genetic testing results if available
- ✓AL amyloidosis: document underlying plasma cell dyscrasia
- ✓Cardiac amyloidosis: assess and document NYHA functional class
Common pitfalls to avoid
Coding requires distinguishing AL, ATTR, or other types for accurate reimbursement and clinical data. Miscoding subtype impacts treatment and outcomes analysis.
Cardiac amyloidosis can mimic other cardiomyopathies. Accurate documentation of amyloid protein typing is crucial for correct code assignment and avoiding undercoding severity.
If cardiac involvement isn't explicitly documented in AL amyloidosis, coders may miss secondary codes impacting quality metrics and resource allocation related to heart failure.
Best-practice tips
- 01Document ATTR-CM, AL amyloidosis for ICD-10 coding accuracy.
- 02Code cardiac amyloidosis subtypes: ATTR, AL, familial.
- 03Query for amyloid type, NYHA class for CDI, risk adjustment.
- 04Ensure complete echo, biopsy reports for compliant billing.
- 05Review Mayo Clinic criteria for diagnostic clarity, compliance.
Step-by-step checklist
- 1
1. Unexplained LVH or HF symptoms? Consider Cardiac Amyloidosis (ATTR-CM, AL Amyloidosis)
- 2
2. ECG: Low voltage, pseudo-infarct pattern? Document findings for Amyloid Cardiomyopathy diagnosis.
- 3
3. Biopsy (endomyocardial, fat pad) planned/performed? Code for Amyloidosis evaluation and staging.
- 4
4. Imaging (ECHO, CMR): Speckle pattern, wall thickening? Supports Cardiac Amyloidosis ICD-10 coding.
Ready-to-paste narrative
Patient presents with signs and symptoms suggestive of cardiac amyloidosis, including dyspnea, fatigue, peripheral edema, and orthopnea. Differential diagnosis includes amyloid cardiomyopathy, ATTR-CM (transthyretin amyloid cardiomyopathy), and AL amyloidosis with cardiac involvement. Physical examination reveals jugular venous distension, diminished heart sounds, and a third heart sound (S3). Electrocardiogram (ECG) shows low voltage QRS complexes and may exhibit a pseudo-infarct pattern. Echocardiography demonstrates thickened left ventricular walls with characteristic granular sparkling appearance, diastolic dysfunction, and potential right heart involvement. Cardiac biomarkers, such as BNP (brain natriuretic peptide) and NT-proBNP (N-terminal pro-B-type natriuretic peptide), are often elevated. Further workup may include cardiac magnetic resonance imaging (CMR) for tissue characterization, bone scintigraphy for ATTR-CM evaluation, and serum and urine protein electrophoresis with immunofixation to assess for AL amyloidosis. A definitive diagnosis often requires endomyocardial biopsy. Treatment strategies focus on managing heart failure symptoms with diuretics, ACE inhibitors, and beta-blockers. Disease-modifying therapies, such as tafamidis or patisiran for ATTR-CM and chemotherapy regimens for AL amyloidosis, may be considered based on the underlying amyloid type. Patient education regarding prognosis, lifestyle modifications, and follow-up care is essential. ICD code I42.6 is used for coding cardiac amyloidosis in medical billing and healthcare documentation.
Common questions and answers
How can I differentiate between AL amyloidosis with cardiac involvement and ATTR-CM in my differential diagnosis, considering both present with similar symptoms like heart failure?+
Differentiating AL amyloidosis with cardiac involvement and ATTR-CM requires a multi-faceted approach. While both can present with heart failure symptoms, key distinctions exist. AL amyloidosis, caused by immunoglobulin light chain deposition, often involves other organs like the kidneys and liver, and presents with a more rapid decline. ATTR-CM, stemming from transthyretin protein misfolding, may manifest with peripheral neuropathy, carpal tunnel syndrome, or autonomic dysfunction. Biopsy (abdominal fat pad, bone marrow, or endomyocardial) is crucial for tissue diagnosis. Serum free light chain assay, immunofixation electrophoresis, and genetic testing for transthyretin mutations are essential for definitive typing. Consider implementing a diagnostic algorithm incorporating these tests to distinguish between these two forms of cardiac amyloidosis. Explore how advanced imaging techniques like cardiac MRI and DPD scintigraphy can further aid in diagnosis and risk stratification. Learn more about the specific treatment approaches for each type once a definitive diagnosis is established.
What are the latest evidence-based guidelines for managing cardiac amyloidosis stages, including specific treatment options for both ATTR-CM and AL amyloidosis?+
Managing cardiac amyloidosis depends on accurate staging and amyloid typing (ATTR or AL). For ATTR-CM, tafamidis and diflunisal stabilize transthyretin tetramers, slowing disease progression. In some cases, liver transplantation may be considered for hereditary ATTR-CM. For AL amyloidosis, chemotherapy regimens targeting plasma cells are the mainstay of treatment, aiming to reduce amyloidogenic light chain production. Supportive care for heart failure, including diuretics, ACE inhibitors, and beta-blockers, is crucial for both types. However, careful consideration of medication interactions and potential side effects is necessary, especially in patients with advanced cardiac dysfunction. Explore how emerging therapies, such as gene silencing and antibody-based treatments, are expanding treatment options for both ATTR-CM and AL amyloidosis. Consider implementing a multidisciplinary approach involving cardiologists, hematologists, and other specialists for optimal patient management according to the latest evidence-based guidelines.
What are the red flags in patient history and physical exam findings that should raise my suspicion for cardiac amyloidosis, and prompt further investigation beyond a routine heart failure workup?+
While cardiac amyloidosis can mimic other forms of heart failure, several red flags should raise suspicion. Unexplained left ventricular hypertrophy with a restrictive filling pattern on echocardiography, especially in the absence of hypertension, is a key finding. Consider cardiac amyloidosis if your patient presents with heart failure symptoms alongside peripheral neuropathy, carpal tunnel syndrome, autonomic dysfunction (e.g., orthostatic hypotension, erectile dysfunction), or macroglossia. Other red flags include a history of unexplained nephrotic syndrome, hepatomegaly, or soft tissue purpura. If these findings are present in conjunction with an elevated NT-proBNP and troponin, especially disproportionate to the degree of left ventricular dysfunction, further investigation beyond a routine heart failure workup is warranted. Learn more about the utility of serum free light chain assay and bone marrow biopsy in evaluating suspected cardiac amyloidosis. Consider implementing early diagnostic testing for cardiac amyloidosis to improve patient outcomes, as prompt diagnosis is crucial for initiating appropriate therapy.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.